Metrion Biosciences Names Lee Patterson as New CEO

• Metrion Biosciences has named Lee Patterson as CEO, effective 2nd December 2024.

• Patterson succeeds Dr Andrew Southan, who led the company through five years of significant growth.

Metrion Biosciences, a specialist preclinical contract research organisation (CRO), has appointed Lee Patterson as its new CEO. Effective from 2nd December 2024, Patterson brings a wealth of experience in the life sciences and CRO sectors to the role, succeeding Dr Andrew Southan, who has stepped down after five successful years as CEO.

Patterson is well-known for his leadership in the CRO industry, having previously served as CEO at Charnwood Discovery, where he led the company through its acquisition by Concept Life Sciences earlier this year. His extensive career also includes leadership positions at Quanticate, Concept Life Sciences, and Covance/Labcorp. At Metrion, Patterson will work alongside Chief Commercial Officer Dr Chris Mathes to strengthen the company’s global footprint and scientific expertise.

Under Dr Andrew Southan’s leadership, Metrion more than doubled its revenue, expanded its laboratory facilities, and grew its international client base. Southan also successfully closed a £3.7M equity financing round in 2023.

Keith McCullagh, Chairman of Metrion Biosciences, expressed gratitude for Southan’s leadership and optimism for Patterson’s appointment. “Lee Patterson’s extensive experience in commercial CROs and operational efficiencies will help Metrion continue its growth as a specialist CRO serving global markets,” he stated.

Patterson commented on his new role, saying, “Metrion Biosciences has built an impressive reputation in ion channel drug discovery. I am excited to join this talented team and look forward to enhancing and expanding our specialised services to meet the needs of our clients worldwide.”